Amphithéâtre 250
3175, Chemin de la Côte-Sainte-Catherine
Montréal (QC) Canada  H3T 1C5

Conférence scientifique | Centre de recherche du CHU Sainte-Justine

Conférencier :
Yannick Doyon, PhD (invitée pour l'axe Santé métabolique et cardiovasculaire)

  • Chercheur régulier, Axe Reproduction, santé de la mère et de l’enfant, Centre de recherche du CHU de Québec – Université Laval
  • Professeur adjoint, Département de médecine moléculaire, Université Laval

Biographie :
I established my laboratory at the CHU de Québec–Université Laval research center in September 2013 after a seven-year postdoctoral stint in the biotechnology sector (Sangamo Therapeutics, California, USA) devoted to the creation and implementation of genome-editing tools. My team develops versatile methods for increasing the efficacy of targeted genome editing to enable the creation of bona fide cellular models for biological research. In addition, we explore the potential of in vivo genome editing as a novel class of human therapeutics for pediatric metabolic disorders.

Résumé :
In this seminar, I will share our recent results demonstrating that CRISPR-Cas9 systems can be used to dissect metabolic pathways in vivo. Using a mouse model of hereditary tyrosinemia, we uncovered intra-pathway enhancers and suppressors that modulate the phenotype and the levels of key catabolites of the pathway. I will also describe our approach to streamline the incorporation of marker-free genetic changes in human cells (Agudelo et al, Nature methods 2017).

In vivo metabolic rewiring via CRISPR-Cas9-based genome editing